[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 332
Citations 0
Lab Reports
March 5, 2014

Anticancer Drugs Reduce Type 1 Diabetes Incidence in Mice

JAMA. 2014;311(9):894. doi:10.1001/jama.2014.1870

Low doses of lysine deacetylase inhibitors, which are used to treat lymphoma, can prevent the host immune response from attacking insulin-producing beta cells in mice that would otherwise develop type 1 diabetes, reports a team led by researchers at the University of Copenhagen, in Denmark (Christensen DP et al. Proc Natl Acad Sci U S A. 2014;111[3]:1055-1059).

The anticancer drugs were given at 100-fold lower concentrations than doses needed to reduce tumor size in vitro and in animals. When weaning mice received vorinostat or givinostat in their drinking water until 100 to 120 days, diabetes incidence was reduced from 50% to 12% and from 69% to 25%, respectively. Treatment increased insulin production and caused fewer immune cells to enter the pancreas, with a 16% increase in the percentage of islets without immune cell infiltration.

First Page Preview View Large
First page PDF preview
First page PDF preview
×